Condition
Recurrent Ovarian Transitional Cell Carcinoma
Total Trials
2
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Active Not Recruiting2
Clinical Trials (2)
Showing 2 of 2 trials
NCT04092270Phase 1Active Not Recruiting
A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer
NCT04739800Phase 2Active Not Recruiting
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Showing all 2 trials